SU1453661A1 - Противоопухолевое средство "продимин - Google Patents

Противоопухолевое средство "продимин Download PDF

Info

Publication number
SU1453661A1
SU1453661A1 SU721848995A SU1848995A SU1453661A1 SU 1453661 A1 SU1453661 A1 SU 1453661A1 SU 721848995 A SU721848995 A SU 721848995A SU 1848995 A SU1848995 A SU 1848995A SU 1453661 A1 SU1453661 A1 SU 1453661A1
Authority
SU
USSR - Soviet Union
Prior art keywords
patients
treatment
drug
course
patient
Prior art date
Application number
SU721848995A
Other languages
English (en)
Russian (ru)
Inventor
Т.С. Сафонова
В.А. Чернов
С.М. Минакова
К.В. Левшина
Т.А. Андрианова
Н.А. Гринева
Original Assignee
Всесоюзный научно-исследовательский химико-фармацевтический институт им.Серго Орджоникидзе
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Всесоюзный научно-исследовательский химико-фармацевтический институт им.Серго Орджоникидзе filed Critical Всесоюзный научно-исследовательский химико-фармацевтический институт им.Серго Орджоникидзе
Priority to SU721848995A priority Critical patent/SU1453661A1/ru
Priority to GB4001273A priority patent/GB1428044A/en
Priority to DE19732343809 priority patent/DE2343809A1/de
Priority to FR7339101A priority patent/FR2206938B1/fr
Application granted granted Critical
Publication of SU1453661A1 publication Critical patent/SU1453661A1/ru

Links

Landscapes

  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
SU721848995A 1972-11-17 1972-11-17 Противоопухолевое средство "продимин SU1453661A1 (ru)

Priority Applications (4)

Application Number Priority Date Filing Date Title
SU721848995A SU1453661A1 (ru) 1972-11-17 1972-11-17 Противоопухолевое средство "продимин
GB4001273A GB1428044A (en) 1972-11-17 1973-08-23 Antitumorigenic compositions
DE19732343809 DE2343809A1 (de) 1972-11-17 1973-08-30 Arzneimittel mit antigeschwulstwirkung
FR7339101A FR2206938B1 (it) 1972-11-17 1973-11-02

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SU721848995A SU1453661A1 (ru) 1972-11-17 1972-11-17 Противоопухолевое средство "продимин

Publications (1)

Publication Number Publication Date
SU1453661A1 true SU1453661A1 (ru) 1989-10-30

Family

ID=20532792

Family Applications (1)

Application Number Title Priority Date Filing Date
SU721848995A SU1453661A1 (ru) 1972-11-17 1972-11-17 Противоопухолевое средство "продимин

Country Status (4)

Country Link
DE (1) DE2343809A1 (it)
FR (1) FR2206938B1 (it)
GB (1) GB1428044A (it)
SU (1) SU1453661A1 (it)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2456983C2 (ru) * 2006-11-28 2012-07-27 Новартис Аг Комбинация ингибиторов iap и flt3
RU2605603C1 (ru) * 2015-06-19 2016-12-27 Федеральное государственное бюджетное учреждение науки Институт проблем химической физики Российской академии наук (ИПХФ РАН) N,n'-бис(3-бромпропионил)-n,n'-диметил-1,2-этилендиамин, способ его получения и применение его в качестве водорастворимого реагента, проявляющего противоопухолевые свойства

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Prod.et probl.pharm., , № 4, р,276. *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2456983C2 (ru) * 2006-11-28 2012-07-27 Новартис Аг Комбинация ингибиторов iap и flt3
RU2605603C1 (ru) * 2015-06-19 2016-12-27 Федеральное государственное бюджетное учреждение науки Институт проблем химической физики Российской академии наук (ИПХФ РАН) N,n'-бис(3-бромпропионил)-n,n'-диметил-1,2-этилендиамин, способ его получения и применение его в качестве водорастворимого реагента, проявляющего противоопухолевые свойства

Also Published As

Publication number Publication date
FR2206938A1 (it) 1974-06-14
FR2206938B1 (it) 1977-02-18
DE2343809A1 (de) 1974-06-06
GB1428044A (en) 1976-03-17

Similar Documents

Publication Publication Date Title
Creagan et al. Phase II study of recombinant leukocyte A interferon (rIFN‐αA) in disseminated malignant melanoma
Poplack et al. Phase I study of 2′-deoxycoformycin in acute lymphoblastic leukemia
Dover et al. Hydroxyurea induction of hemoglobin F production in sickle cell disease: relationship between cytotoxicity and F cell production
Selawry et al. Vincristine treatment of cancer in children
Allen et al. Oxymetholone therapy in aplastic anemia
Rosenthal et al. The use of adrenocorticotropic hormone and cortisone in the treatment of leukemia and leukosarcoma
EP0774255B1 (en) Use of ursolic acid for the manufacture of a medicament for suppressing metastasis
Teklu et al. Meptazinol diminishes the Jarisch-Herxheimer reaction of relapsing fever
EP1443933B1 (en) Treatment of chronic myelogenous leukemia, resistant or intolerant to sti571, involving homoharringtonine alone or combined with other agents
Sokal et al. Evidence for a selective antileukemic effect of cytosine arabinoside in chronic granulocytic leukemia
EP0821963A1 (en) Anticancer substance suppressing cancerous metastasis
US4806347A (en) Interferon combinations
Nissen et al. Phase I Clinical Trial of an Oral Solution of VP-16-2131, 2
SU1453661A1 (ru) Противоопухолевое средство "продимин
Martoni et al. Activity of 4-demethoxydaunorubicin by the oral route in advanced breast cancer
Talpaz et al. Recombinant interferon-alpha therapy of Philadelphia chromosome-negative myeloproliferative disorders with thrombocytosis
Herman Effect of Temperature on the Cytotoxicity of Vindesine, Amsacrine, and Mitoxantrone¹, 2
Shimkin et al. Trisethylene-imino-s-triazine (triethylene melamine or TEM) in the treatment of neoplastic diseases
Hagenbeek et al. Treatment of acute myelocytic leukemia with low-dose cytosine arabinoside: results of a pilot study in four patients
Wong et al. Comparative effects of tetrandrine and berbamine on acute and relapsing experimental allergic encephalitis in Lewis rats
Bershof et al. AGRANULOCYTOSIS FOLLOWING USE OF PHENYLBUTAZONE (BUTAZOLIDIN9): REPORT OF A CASE
DE4127469A1 (de) Arzneimittel und ihre verwendung
CN114650826A (zh) 一种多靶点蛋白激酶抑制剂的用途
Suzuki et al. Pure white cell aplasia complicated by systemic sclerosis with accompanying scleroderma renal crisis
CA2229141A1 (en) Combination therapy for advanced cancer comprising temozolomide and cisplatin